Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported compensation-related equity activity. He exercised vested Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing his directly held Class A Ordinary Shares to 15,345.
Quart also received new equity awards on May 29, 2026. He was granted 2,026 RSUs, each representing one Class A Ordinary Share, which vest in full on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. In addition, he received options for 12,158 Class A Ordinary Shares at an exercise price of $48.38, vesting in twelve substantially equal monthly installments over roughly one year.
Kiniksa Pharmaceuticals International, plc director Kimberly J. Popovits reported routine equity compensation transactions. On May 29, 2026, she exercised 2,799 Restricted Share Units into an equal number of Class A Ordinary Shares, bringing her direct Class A Ordinary Share holdings to 15,345 shares after the transaction.
On the same date, she received new awards of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments starting from the May 29, 2026 grant date, and the RSUs vest in full on the earlier of the first anniversary of the grant or the next annual shareholder meeting.
Kiniksa Pharmaceuticals International, plc reported that trusts associated with Chairman and CEO Sanj K. Patel adjusted their holdings of ordinary shares. The Anglia 2013 Revocable Trust converted 900,000 Class B Ordinary Shares into 900,000 Class A Ordinary Shares at a stated price of $0.00 per share, a non-cash derivative conversion rather than a market trade.
After this conversion, the Anglia 2013 Revocable Trust holds 951,794 Class A Ordinary Shares and 626,160 Class B Ordinary Shares. Separate family trusts report indirect holdings of 76,174 and 109,795 Class A Ordinary Shares. The filing reflects changes in share classes held through family trusts, not open-market buying or selling.
Kiniksa Pharmaceuticals International, plc director Tracey L. McCain reported routine equity compensation activity. McCain exercised 2,799 Restricted Share Units (RSUs) into 2,799 Class A Ordinary Shares, bringing direct holdings in the shares to 15,345. The filing also shows a new grant of 2,026 RSUs and a separate grant of share options for 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the May 29, 2026 grant date, while the new RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual shareholder meeting.
Kiniksa Pharmaceuticals director Thomas Malley reported equity compensation transactions and updated holdings. On May 29, 2026, he exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares at a stated price of $0.00 per share.
On the same date, he received a new grant of 2,026 Restricted Share Units and a share option for 12,158 Class A Ordinary Shares with an exercise price of $48.38 per share. The option vests in twelve substantially equal monthly installments following the grant date, with the final installment vesting on the earlier of the first anniversary of the grant or the issuer’s next annual meeting of shareholders.
Following these transactions, Malley directly holds 15,345 Class A Ordinary Shares. An additional 71,967 Class A Ordinary Shares are held indirectly through Mossrock Capital, LLC, where he serves as president and may be deemed to beneficially own those shares.
Kiniksa Pharmaceuticals International, plc director Richard S. Levy reported routine equity compensation activity. He exercised 2,799 Restricted Share Units, receiving the same number of Class A Ordinary Shares, bringing his direct holdings in that class to 21,956 shares.
On the same date, he received new grants of 2,026 Restricted Share Units and a share option covering 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share. Footnotes state the option vests in twelve substantially equal monthly installments over roughly one year, while the new RSUs vest in full on the earlier of the grant anniversary or the company’s next annual shareholder meeting.
Kiniksa Pharmaceuticals International, plc director Cole G. Bradley reported equity compensation transactions. Bradley exercised 2,799 Restricted Share Units that vested in a single installment into the same number of Class A Ordinary Shares, bringing his direct holdings to 15,345 shares. He also received 2,026 new Restricted Share Units that each represent one Class A Ordinary Share, vesting in full on the earlier of the grant anniversary or the next annual shareholder meeting. In addition, he was granted options on 12,158 Class A Ordinary Shares at an exercise price of $48.38 per share, vesting in twelve substantially equal monthly installments and expiring in 2036.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kiniksa Pharmaceuticals International, plc reported compensation-related equity grants to directors affiliated with Baker Bros. funds. On May 29, 2026, each of Felix J. Baker, Dr. Stephen R. Biggar and M. Cantey Boyd received 2,026 restricted share units (RSUs) and 12,158 non-qualified share options tied to Class A Ordinary Shares under the 2018 Incentive Award Plan. The RSUs vest on the earlier of May 29, 2027 or the next annual shareholder meeting, subject to continued board service, while the share options have a strike price of $48.38, vest in 12 monthly installments beginning June 29, 2026, and expire on May 28, 2036. The Form 4 attributes indirect pecuniary interests in these awards to 667, L.P. and Baker Brothers Life Sciences LP, with Baker Bros. Advisors LP holding voting and dispositive power, and Julian C. Baker and Felix J. Baker disclaiming beneficial ownership beyond their pecuniary interests.
Kiniksa Pharmaceuticals International, plc held its Annual Meeting of Shareholders on May 29, 2026, where both Class A and higher-vote Class B shares participated. Each Class A share carried one vote, and each Class B share carried ten votes as of the April 6, 2026 record date.
Shareholders re-elected Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II directors to serve until the 2029 Annual Meeting. All director nominees received substantially more votes for than against, with millions of votes in favor and limited opposition or abstentions.
Investors also approved several auditor and compensation items. They confirmed PricewaterhouseCoopers LLP as UK statutory auditors and ratified PwC as US independent registered public accounting firm for the 2026 fiscal year, and authorized the board, through its audit committee, to set PwC’s remuneration.
Shareholders received the UK statutory annual accounts and report for the period ended December 31, 2025 and supported the UK Statutory Directors’ Annual Remuneration Report, the UK Statutory Directors’ Remuneration Policy, and the advisory vote on named executive officer compensation, each passing with strong majorities and relatively low levels of opposition.
Baker Bros. Advisors and related entities filed Amendment No. 6 to their Schedule 13D for Kiniksa Pharmaceuticals International, plc, reporting beneficial ownership of about 7% of Kiniksa’s Class A ordinary shares. Their percentages are based on 46,303,276 Class A shares outstanding as of April 24, 2026.
On May 21, 2026, Kiniksa and the Adviser signed a Deed of Waiver that limits conversions of the Funds’ Class A1 and Class B1 ordinary shares so that the Funds and certain affiliates will not exceed 49.9% of Kiniksa’s outstanding voting rights. Separate 4.99% beneficial ownership limits and 61‑day notice periods apply to conversions of Class A1 and Class B1 shares. Without these conversion limits, the Reporting Persons may be deemed beneficial owners of 32,107,763 Class A ordinary shares, or about 42.5% of the outstanding Class A shares.